A randomized, double blinded, multi-center phase 2 study to estimate the efficacy and evaluate the safety and tolerability of sorafenib [Nexavar] in combination with AMG 386 or placebo in subjects with metastatic clear cell carcinoma of the kidney

Trial Profile

A randomized, double blinded, multi-center phase 2 study to estimate the efficacy and evaluate the safety and tolerability of sorafenib [Nexavar] in combination with AMG 386 or placebo in subjects with metastatic clear cell carcinoma of the kidney

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Trebananib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 09 Feb 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
    • 21 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2013 to 1 Dec 2014.
    • 27 Nov 2012 Planned End Date changed from 1 Nov 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top